Archana Tamoshunas focuses her practice on complex class action litigation, including antitrust and consumer protection litigation. Ms. Tamoshunas represents direct purchasers of prescription drugs in federal antitrust actions alleging that pharmaceutical manufacturers have wrongfully prevented or delayed less expensive generic drugs from entering the market. Ms. Tamoshunas currently represents class members in several of these pharmaceutical antitrust class actions including, In re Lidoderm Antitrust Litigation (N.D. Cal.), in which her firm is appointed to the Executive Committee, In re Niaspan Antitrust Litigation (E.D. Pa.), In re Solodyn Antitrust Litigation (D. Mass.), In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.) and In re Opana ER Antitrust Litigation (N.D. Ill.). She also represents Giant Eagle, Inc. in King Drug Co. of Florence, Inc. v. Cephalon, Inc. et al. (E.D. Pa.).
Ms. Tamoshunas has also represented direct purchasers in antitrust cases that have been successfully resolved or partially resolved including In re Skelaxin (Metaxalone) Antitrust Litigation (E.D. Tenn.) ($73 million settlement), In re Wellbutrin XL Antitrust Litigation (E.D. Pa.) ($37.5 million settlement with one of two defendants), In re Prandin Direct Purchaser Antitrust Litigation (E.D. Mich.) (Executive Committee) ($19 million settlement) and Mylan Pharmaceuticals v. Warner Chilcott (E.D. Pa.) ($15 million settlement).
Ms. Tamoshunas also represents plaintiffs in Westrope v. Ringler (D. Or.), a class action brought on behalf of structured settlement annuitants who suffered cuts to their annuity payments as a result of their structured settlement brokers’ alleged negligence.
Prior to joining Taus, Cebulash & Landau, LLP in July 2009, Ms. Tamoshunas was an associate at a New York law firm that specialized in class action litigation. At her prior firm, Ms. Tamoshunas was counsel in several complex federal antitrust class actions including those involving the pharmaceutical and medical device industries, as well as employment class actions. She was heavily involved in all aspects of the litigation process in cases in which her firm was lead or co-lead counsel, handling the day to day management of discovery, briefing, class certification and trial preparation in a number of cases including In re Relafen Antitrust Litigation (D. Mass.); In re Terazosin Hydrochloride Antitrust Litigation (S.D. Fla.) and Natchitoches Parish Hospital District et al. v. Tyco International, et al. (D. Mass.).
Ms. Tamoshunas graduated from Williams College, cum laude, in 1995 (B.A. Political Science and Studio Art) and New York University School of Law in 1999, where she was a member of the Moot Court Board and had her case problem published in the New York University School of Law Moot Court Casebook (Vol. 22, 1998). Ms. Tamoshunas is admitted to the Bar of the State of New York as well as the Southern and Eastern Districts of New York, the Eastern District of Michigan and the First Circuit Court of Appeals. She is a member of the Antitrust Law Section of the New York State Bar Association. After graduating from law school, Ms. Tamoshunas represented the City of New York in child abuse and neglect cases in Family Court from 1999 to 2002.